Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-11-30
Based on 381 first isolates · MED-B · Febrile UTI / pyelonephritis · 2024-12-01 → 2025-11-30
Internal medicine B
Per-organism detail: MED-B urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
ciprofloxacin 81 % (77 %–85 %)
Not covered: Enterococcus faecalis (8 %), Escherichia coli (4 %), Staphylococcus aureus (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
meropenem MEM
trend · Escherichia coli reserve
87 %
86 %
n = 22
nitrofurantoin NIT
trend · Escherichia coli not for this site
85 %
77 %
n = 22
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
82 %
77 %
n = 22
ciprofloxacin CIP
trend · Escherichia coli
81 %
86 %
n = 22
ceftriaxone CRO
trend · Escherichia coli
81 %
82 %
n = 22
mecillinam MEC
trend · Escherichia coli not for this site
80 %
82 %
n = 22
77 %
77 %
n = 22
trimethoprim TMP
trend · Escherichia coli not for this site
72 %
77 %
n = 22
48 %
50 %
n = 22
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
12 %
14 %
n = 22
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
3 %
9 %
n = 22
3 %
5 %
n = 22

Most likely organisms for this profile

Escherichia coli
59 %
Klebsiella pneumoniae
12 %
Enterococcus faecalis
8 %
Proteus mirabilis
7 %
Staphylococcus aureus
3 %
Citrobacter freundii
3 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.